Table 1 Main characteristics and results of the eligible studies
First author | Year | Country | Study type | N | Clinical stage | Chemotherapy regimen | pCR rate | Follow-up (median) (year) | HR estimation | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
Clifton | 2018 | USA | Prospective | 319 | I–II | A/T | 0.538 | 6.33 | Survival curve | OS, DFS |
Fisher | 2012 | USA | Retrospective | 385 | I–III | NA | 0.17 | 2.5 | Survival curve | OS |
Kennedy | 2010 | USA | Retrospective | 405 | I–III | NA | NR | 4.3 | Survival curve | OS |
Sharma | 2015 | USA | Retrospective | 146 | I–II | A/T | NR | 3.08 | Given by author | DFS |
Cheng | 2017 | NR | Retrospective | 15,483 | I–III | NA | NR | 2 | Given by author | OS |
Yang | 2018 | China | Prospective | 67 | II–III | A/T | 0.194 | 6.5 | Given by author | OS |
Biswas | 2017 | USA | Retrospective | 420 | I–III | A/T | 0.33 | 3.9 | Survival curve | OS |
Bagegni | 2019 | USA | Retrospective | 19,151 | II-III | NA | 0.474 | 2.5 | Survival curve | OS |
Philipovskiy | 2019 | USA | Retrospective | 104 | I–III | A/T | 0.4 | 6 | Given by author | OS,DFS |